Front Line Medical Technologies is approaching the UK with a different market access strategy in comparison to that for North America in the launch of the company’s aortic occlusion device, said Asha Parekh, Front Line Medical Technologies’ CEO.
Front Line Medical Counts On Fast UK Access For COBRA-OS REBOA Device
Aortic Occlusion Device Maker Plans To Capitalize On UK Prehospital System
The UK's established emergency care prehospital system potentially opens up a faster route to market for Front Line Medical Technologies's aortic occlusion device, COBRA-OS. Asha Parekh, Front Line CEO, talks to Medtech Insight about the company's different strategic approach to UK market access in comparison to North America.
More from Market Access
• By
With the support of AIM-MASH AI Assist only one pathologist is needed to reliably make a histology assessment of inflammatory liver disease to decide whether patients should be included in MASH clinical trials.
• By
Boston Scientific has entered the multi-billion hypertension treatment market with the acquisition of Israel-based startup SoniVie, developer of the TIVUS intravascular ultrasound system for the treatment of high blood pressure by artery nerve ablation.
• By
Only one year in the last decade involved more medtech acquisitions worth over $1bn than 2024, said McKinsey. A new report from the consulting firm found that despite an overall fall in activity for the life science sector, the economic and regulatory environment may support a strong rebound in dealmaking.
• By
AvaSure’s new in-hospital virtual care assistant utilizes Oracle's cloud platform and NVIDIA AI software packages to improve clinical workflow by grading patients’ responses to a question format.
More from Strategy
• By
Dublin-based Neuromod has closed a €10m ($10.9m) series B funding round to bring a "new standard of care" to patients with tinnitus.
• By
Abbott’s international sales could be a key driver as firm looks to partnerships with insulin pump companies.
• By
Tempering expectations on the immediate market impact for the upgraded continuous glucose monitor, Dexcom notes insurance coverage and pump integrations will take time to finalize.